Reirradiation in squamous cell head and neck cancer: Recent developments and future directions

Current Opinion in Oncology

Volumn 19, Issue 3, 2007, Pages 202-209

  Langendijk, Johannes A ^a   Bourhis, Jean ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Head and neck cancer; Reirradiation

Indexed keywords

AMIFOSTINE; BORTEZOMIB; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; PACLITAXEL; TAXANE DERIVATIVE;

CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK CARCINOMA; HUMAN; HYPONATREMIA; HYPOTENSION; INTENSITY MODULATED RADIATION THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; SALVAGE THERAPY; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; SALVAGE THERAPY; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34247096098     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e3280f00ff8     Document Type: Review

References (45)

1. Kasperts N, Slotman B, Leemans CR, Langendijk JA. A review on re-irradiation for recurrent and second primary head and neck cancer. Oral Oncol 2005; 41:225-243.
2. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 2000; 355:949-955.
3. Bourhis J, Overgaard J, Audry H, et al. Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006; 368:843-854. This meta-analysis based on individual patient data, provides level I evidence of the additional value of altered fractionation as compared to conventionally fractionated radiotherapy in squamous cell head and neck cancer.
4. Remenar E, Van Herpen C, Germa Lluch J, et al. A randomized phase III multicenter trial of neoadjuvant docetaxel plus cisplatin and 5-fluorouracil (TPF) versus neoadjuvant PF in patients with locally advanced unresectable squamous cell carcinoma of the head and neck (SCCHN). Final analysis of EORTC 24971 [abstract]. J Clin Oncol 2006; 24 (Suppl 18):5516.
5. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005; 23:8636-8645.
6. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578. This describes the first prospective randomized study to show that the addition of cetuximab to radiation alone significantly impoves outcome in squamous cell head and neck cancer, without increasing toxicity and thus increasing the therapeutic ratio.
7. De Crevoisier R, Domenge C, Wibault P, et al. Full dose reirradiation combined with chemotherapy after salvage surgery in head and neck carcinoma. Cancer 2001; 91:2071-2076.
8. Schaefer U, Micke O, Schueller P, Willich N. Recurrent head and neck cancer: retreatment of previously irradiated areas with combined chemotherapy and radiation therapy-results of a prospective study. Radiology 2000; 216:371-376.
9. Spencer SA, Wheeler RH, Peters GE, et al. Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck. Am J Clin Oncol 1999; 22:1-5.
10. De Crevoisier R, Bourhis J, Domenge C, et al. Full-dose reirradiation for unresectable head and neck carcinoma: experience at the Gustave-Roussy Institute in a series of 169 patients. J Clin Oncol 1998; 16:3556-3562.
11. Weppelmann B, Wheeler RH, Peters GE, et al. Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. Int J Radiat Oncol Biol Phys 1992; 22:1051-1056.
12. Bernier J, Domenge C, Ozsahin M, et al., European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004; 350:1945-1952.
13. Cooper JS, Pajak TF, Forastiere AA, et al., Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 2004; 350:1937-1944.
14. Nagar YS, Singh S, Datta NR. Chemo-reirradiation in persistent/recurrent head and neck cancers. Jpn J Clin Oncol 2004; 34:61-68.
15. Salama JK, Vokes EE, Chmura SJ, et al. Long-term outcome of concurrent chemotherapy and reirradiation for recurrent and second primary head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2006; 64:382-391. This is an important paper in the field of reirradiation in head and neck squamous cell carcinoma, reporting on the results of a number of prospective phase I-II studies performed at the University of Chicago.
16. Datta NR, Nagar YS, Singh S, Naryan L. Loco-regional failures in head and neck cancer: can they be effectively salvaged by nonsurgical therapeutic modalities? Int J Clin Oncol 2003; 8:31-39.
17. Vokes EE, Panje WR, Schilsky RL, et al. Hydroxyurea, fluorouracil, and concomitant radiotherapy in poor-prognosis head and neck cancer: a phase I-II study. J Clin Oncol 1989; 7:761-768.
18. Britten RA, Perdue S, Opoku J, Craighead P. Paclitaxel is preferentially cytotoxic to human cervical tumor cells with low Raf-1 kinase activity: implications for paclitaxel-based chemoradiation regimens. Radiother Oncol 1998; 48:329-334.
19. Hehr T, Classen J, Belka C, et al. Reirradiation alternating with docetaxel and cisplatin in inoperable recurrence of head-and-neck cancer: a prospective phase I/II trial. Int J Radiat Oncol Biol Phys 2005; 61:1423-1431.
20. Kramer NM, Horwitz EM, Cheng J, et al. Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies. Head Neck 2005; 27:406-414.
21. Milano MT, Vokes EE, Salama JK, et al. Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. Int J Radiat Oncol Biol Phys 2005; 61:1096-1106.
22. Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-kappaB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 63:1400-1412.
23. Orlowski RZ, Baldwin AS Jr. NF-κB as a theraputic target in cancer. Trends Mol Med 2002; 8:385-389.
24. Russo SM, Tepper JE, Baldwin AS Jr, et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-κB. Int J Radiat Oncol Biol Phys 2001; 50:183-193.
25. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23:5568-5577.
26. Taussky D, Dulguerov P, Allal AS. Salvage surgery after radical accelerated radiotherapy with concomitant boost technique for head and neck carcinomas. Head Neck 2005; 27:182-186.
27. Temam S, Pape E, Janot F, et al. Salvage surgery after failure of very accelerated radiotherapy in advanced head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005; 62:1078-1083.
28. McLaughlin MP, Parsons JT, Fein DA, et al. Salvage surgery after radiotherapy failure in T1-T2 squamous cell carcinoma of the glottic larynx. Head Neck 1996; 18:229-235.
29. Ganly I, Patel SG, Matsuo J, et al. Results of surgical salvage after failure of definitive radiation therapy for early-stage squamous cell carcinoma of the glottic larynx. Arch Otolaryngol Head Neck Surg 2006; 132:59-66.
30. Agra IM, Carvalho AL, Ulbrich FS, et al. Prognostic factors in salvage surgery for recurrent oral and oropharyngeal cancer. Head Neck 2006; 28:107-113.
31. Langendijk JA, Slotman BJ, van der Waal I, et al. Risk-group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 2005; 104:1408-1417.
32. Kasperts N, Slotman BJ, Leemans CR, et al. Results of postoperative reirradiation for recurrent or second primary head and neck carcinoma. Cancer 2006; 106:1536-1547.
33. Bourhis J, De Racourt D, Castaing M, et al. Re-irradiation combined with chemotherapy after salvage surgery in head and neck carcinoma: A randomised trial from the GORTEC and GETTEC [abstract]. Radiother Oncol 2006; 81 (Suppl 1):S147.
34. Gregoire V, Coche E, Cosnard G, et al. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 2000; 56:135-150.
35. Weiss MH, Harrison LB, Isaacs RS. Use of decision analysis in planning a management strategy for the stage N0 neck. Arch Otolaryngol Head Neck Surg 1994; 120:699-702.
36. Langlois D, Eschwege F, Kramar A, Richard JM. Reirradiation of head and neck cancers. Presentation of 35 cases treated at the Gustave Roussy Institute. Radiother Oncol 1985; 3:27-33.
37. Langendijk JA, Kasperts N, Leemans CR, et al. A phase II study of primary reirradiation in squamous cell carcinoma of head and neck. Radiother Oncol 2006; 78:306-312.
38. Vergeer MR, Doornaert P, Leemans CR, et al. Control of nodal metastases in squamous cell head and neck cancer treated by radiation therapy or chemoradiation. Radiother Oncol 2006; 79:39-44.
39. Ernst-Stecken A, Lambrecht U, Mueller R, et al. Dose escalation in large anterior skull-base tumors by means of IMRT. First experience with the Novalis system. Strahlenther Onkol 2006; 182:183-189.
40. Paulino AC, Koshy M, Howell R, et al. Comparison of CT- and FDG-PET-defined gross tumor volume in intensity-modulated radiotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2005; 61:1385-1392.
41. Phillips TL, Kane L, Utley JF. Radioprotection of tumor and normal tissues by thiophosphate compounds. Cancer 1973; 32:528-535.
42. Yuhas JM, Spellman JM, Culo F. The role of WR-2721 in radiotherapy and/or chemotherapy. Cancer Clin Trials 1980; 3:211-216.
43. Brizel DM, Wasserman TH, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18:3339-3345.
44. Jellema AP, Slotman BJ, Muller MJ, et al. Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. Cancer 2006; 107:544-553.
45. Machtay M, Rosenthal DI, Chalian AA, et al. Pilot study of postoperative reirradiation, chemotherapy, and amifostine after surgical salvage for recurrent head-and-neck cancer. Int J Radiat Oncol Biol Phys 2004; 59:72-77.